Vagus Nerve Stimulation for Rheumatoid Arthritis：What Research Shows About This Emerging Treatment
Vagus nerve stimulation for rheumatoid arthritis is no longer only a laboratory idea, but the answer depends on the device. In the United States, the FDA approved the implanted SetPoint System in 2025 for a defined group of adults with moderately to severely active RA who have had an inadequate response, loss of response, or intolerance to biologic or targeted synthetic DMARDs. ([1]) That approval does not apply to every vagus nerve device, every person with RA, or ear-based consumer stimulation.
The research is still developing in important ways. The best evidence is for a surgically implanted system used under specialist care. Non-invasive ear-based vagus nerve stimulation, often called transcutaneous auricular VNS or taVNS, has shown mixed and early results. It should not be treated as interchangeable with the approved implant or as a substitute for a rheumatology treatment plan. ([2]) ([5])
Is Vagus Nerve Stimulation a Treatment for Rheumatoid Arthritis
For the specific FDA-approved indication, yes: the SetPoint System is an implanted vagus nerve stimulator intended for adults with moderately to severely active RA after inadequate response, loss of response, or intolerance to one or more biologic or targeted synthetic DMARDs. It is not a general over-the-counter treatment and requires a surgical implant next to the left cervical vagus nerve. ([1])
For other forms of VNS, the answer is more limited. A device being researched in a clinic, a neck-worn stimulator, and an ear-based wellness device have different stimulation sites, protocols, safety considerations, and evidence. “Vagus nerve stimulation” describes a category, not a single treatment. This distinction is the most useful starting point when reading claims about rheumatoid arthritis and the vagus nerve. ([2]) ([8])
Why Researchers Connected the Vagus Nerve and Rheumatoid Arthritis
RA is an immune-mediated inflammatory disease. Immune cells and inflammatory mediators such as tumor necrosis factor alpha (TNF-alpha) help drive synovitis, pain, and joint damage. Drug therapies target parts of this biology. VNS research asks a different question: can a neural circuit influence inflammatory signaling enough to improve disease activity in selected patients? ([3])
The proposed biology is often called the inflammatory reflex. Signals related to inflammation are integrated through neural pathways; vagus nerve activity is one part of the broader autonomic output that can influence cytokine production. That is not the same as “turning inflammation off.” It is a physiologic pathway that researchers are trying to modulate with carefully specified stimulation. ([3])
How Could VNS Influence Inflammatory Pathways
A simplified sequence looks like this: inflammatory signals are detected in the body, the brainstem and autonomic nervous system process relevant input, and downstream neural-immune signaling can affect immune-cell cytokine output. The cholinergic anti-inflammatory pathway is one proposed component of this communication. The pathway is scientifically plausible, but it does not mean every device that claims to “stimulate the vagus nerve” produces the same biological effect. ([3])
Dose, waveform, location, timing, participant population, and whether stimulation truly engages the intended nerve branch all matter. Those variables help explain why results from implanted VNS cannot simply be carried over to auricular stimulation. ([2]) ([8])
What Does the Research Show So Far
The pivotal RESET-RA trial offers the strongest current evidence for implanted therapy. In this double-blind, sham-controlled study, 242 participants with inadequate response or intolerance to advanced RA therapies received an implanted system and were assigned to active stimulation or sham stimulation for three months. The ACR20 response at three months was 35.2% with active stimulation and 24.2% with sham (P = 0.0209). After the controlled period, all participants received active stimulation, so later open-label results are useful but less suitable for a sham-controlled comparison. ([2])
Earlier studies helped establish the signal but were smaller. A 2016 implanted-device study reported reduced stimulated blood cytokine production and improvement in RA disease-activity measures. A 2020 randomized pilot in 14 people with multidrug-refractory RA was designed mainly around safety and feasibility; it supported larger sham-controlled evaluation but was too small to settle effectiveness on its own. ([3]) ([4])
|
Study
|
Approach
|
What it adds
|
Key limit
|
|
Tesser et al. 2026 [2]
|
Implanted VNS; 242-person randomized sham-controlled trial
|
Primary endpoint favored active stimulation at 3 months
|
Open-label follow-up cannot replace the controlled comparison
|
|
Koopman et al. 2016 [3]
|
Implanted VNS; early clinical study
|
Linked cytokine findings with disease-activity change
|
Small early study
|
|
Genovese et al. 2020 [4]
|
Miniaturized implanted VNS; 14-person pilot
|
Safety and feasibility data in refractory RA
|
Very small sample
|
|
Baker et al. 2023 [5]
|
Auricular VNS; 113-person sham-controlled trial
|
ACR20 at 12 weeks did not differ from sham
|
One protocol and device; not evidence for all ear-based approaches
|
|
Parikh et al. 2026 [8]
|
Home respiratory-gated taVNS; 12-person feasibility study
|
Home delivery and adherence were feasible
|
Single-arm, uncontrolled; not powered for efficacy
|
Table 1. Evidence map for vagus nerve stimulation approaches in RA. Study designs and devices are not interchangeable.
This mixed evidence is especially important for ear-based VNS. In the 2023 randomized, double-blind trial of 113 participants with active RA, the active and sham groups had similar ACR20 responses at week 12 (25.0% versus 26.9%; P = 0.823). A proof-of-concept study and small open-label studies can be useful for generating hypotheses, but they do not override a sham-controlled result. ([5]) ([6]) ([7])
There are also questions that a successful pivotal trial cannot answer by itself. Researchers still need longer real-world follow-up, clear estimates of who is most likely to benefit, and evidence on how the implanted system fits with medication changes over time. The FDA approval includes post-approval monitoring of safety, device performance, and clinical outcomes, a reminder that approval and continued evidence generation can happen together. ([1])
When reading a VNS headline, look beyond the phrase “reduced inflammation.” Ask whether the outcome was a laboratory marker, a patient-reported symptom, ACR20 response, disease activity score, imaging result, or a feasibility measure. Those endpoints answer different questions. A device can be practical to use at home without yet demonstrating disease-modifying benefit, while a surgically implanted system can have stronger efficacy data but a different risk and access profile. ([2]) ([8])
Implanted VNS and Ear Based taVNS Are Different
Implanted VNS for RA involves an outpatient surgical procedure to position a medical device near the cervical vagus nerve. The FDA-approved SetPoint System belongs in this category. Its indication is narrow, and implantation introduces procedure-related considerations that a specialist team should discuss. ([1]) ([2])
Ear-based taVNS uses electrodes at parts of the outer ear that may be supplied by the auricular branch of the vagus nerve. It avoids surgery, but “non-invasive” does not mean “proven for RA.” Protocols differ in ear site, frequency, pulse width, intensity, session length, and whether stimulation is synchronized to breathing. A 2026 home-based feasibility study enrolled 12 people with active RA. It found good session completion and no severe treatment-emergent adverse events, but its single-arm design cannot show that the device caused symptom or biomarker changes. ([8])
Figure 1. Participant kit used for home respiratory-gated taVNS in an RA feasibility study. Reproduced unchanged from Parikh et al. [8] under CC BY 4.0. This research prototype is not the FDA-approved implanted SetPoint System.
Can VNS Replace Rheumatoid Arthritis Medication
Do not stop, reduce, or delay prescribed RA medication because of VNS information online. RA treatment decisions typically use a treat-to-target approach and disease-modifying antirheumatic drugs remain central to management. Even the approved implanted VNS indication is for a selected population after insufficient response, loss of response, or intolerance to advanced therapies; it is not a blanket replacement for medication. ([1]) ([9])
A rheumatologist can put device options in context with disease activity, prior medication response, infection risk, imaging, pregnancy plans, surgery considerations, and access. If a clinician believes a person may be eligible for the approved system, the discussion should cover the procedure, expected monitoring, contraindications, and alternatives rather than treating VNS as a self-directed add-on. ([1])
What to Consider Before Trying a Vagus Nerve Device
-
Ask which exact device and stimulation site are being discussed. Evidence for a neck implant does not establish benefit for an ear device.
-
Ask whether the device is FDA-approved for RA, cleared or approved for another indication, or sold as a wellness product. These are different regulatory categories.
-
Look for a sham-controlled RA trial, not only studies in healthy participants or other conditions.
-
Review safety with a clinician, especially if you have an implanted electrical device, an upcoming procedure, active ear or skin problems, unexplained fainting, or a complex medical history.
-
Keep expectations specific: a wellness device may support a calming routine, but it should not be presented as a treatment for RA or a way to reduce inflammation.
Optional wellness context. ZenoWell Luna Plus is an ear-based, non-invasive stimulation device designed around autonomic-regulation and wellness routines. It is not the FDA-approved implanted RA therapy, and its use should not be interpreted as treatment for rheumatoid arthritis, a substitute for DMARDs, or a claim of reduced inflammation. People considering any device alongside RA care should review the plan with their rheumatology team.
Figure 2. Two-week protocol from a home respiratory-gated taVNS feasibility study in RA. Reproduced unchanged from Parikh et al. [8] under CC BY 4.0. The figure shows why feasibility work is not the same as a controlled efficacy trial.
Frequently Asked Questions
Does vagus nerve stimulation help rheumatoid arthritis
An implanted system has FDA approval for a specific group of adults with moderately to severely active RA after inadequate response, loss of response, or intolerance to biologic or targeted synthetic DMARDs. That evidence should not be generalized to every VNS device. Ear-based non-invasive VNS remains an active research area with mixed and limited RA-specific results. ([1]) ([5])
Is the vagus nerve connected to rheumatoid arthritis
Researchers study the connection because vagus nerve signaling is part of neural-immune communication that can influence cytokine production. The connection is biologically meaningful, but it does not make RA a condition that can be self-treated by generic “vagus nerve activation” techniques. ([3])
Is non-invasive VNS the same as implanted VNS
No. The FDA-approved RA system is implanted near the cervical vagus nerve. Ear-based taVNS is non-invasive and uses the outer ear. Their access routes, stimulation parameters, device oversight, and evidence bases differ. ([1]) ([8])
What is the main takeaway
Vagus nerve stimulation is a genuine new part of the RA treatment conversation, but precision matters. The approved implanted system is a specialist option for a defined treatment-experienced population. Non-invasive ear-based VNS is promising to study, yet it has not established the same RA treatment role. Use the device name, study design, and FDA indication to judge a claim, and make medication or procedure decisions with a rheumatology team. ([1]) ([2])
References
[1] U.S. Food and Drug Administration. Premarket Approval P240039: SetPoint System. Decision date July 30, 2025. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pma.cfm?id=P240039
[2] Tesser JRP, Crowley AR, Box EJ, et al. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial. Nature Medicine. 2026;32:369-378. doi:10.1038/s41591-025-04114-7.
[3] Koopman FA, Chavan SS, Miljko S, et al. Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(29):8284-8289. doi:10.1073/pnas.1605635113.
[4] Genovese MC, Gaylis NB, Sikes D, et al. Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study. Lancet Rheumatology. 2020;2(9):e527-e538. doi:10.1016/S2665-9913(20)30172-7.
[5] Baker MC, Kavanagh S, Cohen S, et al. A randomized, double-blind, sham-controlled, clinical trial of auricular vagus nerve stimulation for the treatment of active rheumatoid arthritis. Arthritis & Rheumatology. 2023;75(12):2107-2115. doi:10.1002/art.42637.
[6] Marsal S, Corominas H, de Agustín JJ, et al. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study. Lancet Rheumatology. 2021;3(4):e262-e269. doi:10.1016/S2665-9913(20)30425-2.
[7] Drewes AM, et al. Short-term transcutaneous non-invasive vagus nerve stimulation may reduce disease activity and pro-inflammatory cytokines in rheumatoid arthritis: results of a pilot study. Scandinavian Journal of Rheumatology. 2021;50(1):20-27. doi:10.1080/03009742.2020.1764617.
[8] Parikh A, Lewis G, Almesfer F, et al. Home-based respiratory-gated transcutaneous auricular vagus nerve stimulation for rheumatoid arthritis: a feasibility study. Clinical Rheumatology. 2026. doi:10.1007/s10067-026-08041-x. CC BY 4.0 figures reproduced unchanged in this article.
[9] Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care & Research. 2021;73(7):924-939. doi:10.1002/acr.24596.
Related Posts
World Bipolar Day: How Vagus Nerve Stimulation May Support Better Mental Health
March 30 marks World Bipolar Day and also the birthday of Vincent van Gogh. This coincidence offers more than a symbolic moment. It invites us...
Oct 27 2026
研究前沿｜迷走神經刺激器植入後的大型語言模型縱向症狀追蹤
簡介 植入迷走神經刺激（VNS）裝置後，患者狀況隨時間的變化通常會記錄在臨床紀錄中。這些紀錄可能描述患者在個別就診時的癲癇發作、情緒或疼痛。然而，由於紀錄格式缺乏結構，若要系統性比較數年間的變化，會相當困難。 2026 年發表於 JAMIA Open 的一項研究，評估大型語言模型（LLM）是否能從臨床紀錄中擷取症狀和嚴重程度評分，以建立患者層級的縱向變化軌跡。研究的主要重點，是評估一種臨床資訊擷取方法的表現。由此產生的變化軌跡，也初步呈現了患者之間的差異。 背景 臨床紀錄的限制 臨床紀錄必須區分「明確記載為不存在的症狀」與「未被提及的症狀」。前者表示該次就診曾進行相關評估；後者則不提供任何有關症狀狀態的資訊。紀錄中也可能提到某項持續存在的症狀，但沒有足夠細節可以判定其嚴重程度。如果把所有這類紀錄都分類為症狀不存在，就會在縱向變化估計中引入錯誤。 標準化量表可以提供一致的症狀評估，但不一定會在每次例行就診時完成。因此，研究人員檢視了是否能從現有臨床紀錄中可靠地擷取症狀，並追蹤其隨時間的變化。在使用這些紀錄進行更詳細的縱向分析之前，這是必要的方法學步驟。 方法 症狀擷取與嚴重程度分類 研究人員建立了 5 個資料集，共包括 95 名患者和 1,427 份由人工標註的臨床紀錄。訓練資料主要來自與 COVID 相關的紀錄，並加入接受 VNS 或其他手術照護患者的額外紀錄。資料以患者為單位，分為訓練集（58...
Oct 23 2026
SPARC 十年歷程與超過 3.5 億美元資助：從神經定位到精準迷走神經調節
簡介 心跳、胃腸蠕動與膀胱充盈，都受到自律神經系統調節。研究人員希望透過電刺激影響神經活動，為器官功能障礙開發新的介入方式。然而，要準確地將刺激導向與疾病相關的神經纖維，並產生可重複的器官反應，仍需要回答幾個具體問題。神經會投射到哪些位置？不同個體之間的差異有多大？刺激後哪些功能會改變？又要如何及時偵測刺激目標以外的影響？ 2026 年，Bhavesh Patel 及其同事在 Bioelectronic Medicine 發表綜述，整理美國國立衛生研究院（NIH）Stimulating Peripheral Activity to Relieve Conditions（SPARC）計畫的主要成果。該計畫於 2015 年啟動，向近 100 個研究項目提供超過 3.5 億美元資助，並促成 500 多篇出版物。 這篇綜述說明，神經圖譜、科技工具與開放資源如何共同支持精準神經調節。文章也指出，將基礎研究轉化為臨床應用時，仍然存在許多挑戰。 精準神經調節的主要挑戰 迷走神經將大腦與多個內部器官連接起來，是生物電子醫學的重要目標。然而，單一神經內含有走向與功能不同的神經纖維，因此刺激可能同時影響目標器官與其他生理過程。電極放置位置、神經束組織方式與刺激參數，會共同決定哪些神經纖維被招募。...
Oct 23 2026
迷走神經刺激療法中，TENS貼片該貼在哪裡？
TENS 貼片該貼在哪裡才能刺激迷走神經？ 如果你正在找 TENS 貼片該貼在哪裡才能刺激迷走神經，直接的回答是：不要把一般 TENS 貼片貼在脖子前方或側面。頸部包含頸動脈竇與主要神經，未經規範的電刺激可能對它們造成危險影響。對於非侵入性迷走神經刺激，最常被討論的做法是耳部刺激，也稱為 taVNS（經皮耳部迷走神經刺激）。不過，標準方形 TENS 貼片並不適合耳朵——耳朵彎曲的解剖構造需要耳夾電極或專為耳朵設計的形式。相關的耳部區域包括耳屏、耳甲艇與耳甲腔。如果你想要更簡單、更可靠、不必自行摸索的日常流程，專為耳部穿戴設計的 taVNS 裝置，例如 ZenoWell Vita 或 ZenoWell Luna，可能比硬把標準 TENS 機改裝上去更好。 主要擺放區域：耳部迷走神經刺激 如果你的目標是刺激迷走神經——無論是透過 TENS 機、耳夾，還是專用裝置——最實用且最有實證支持的做法，就是耳部迷走神經刺激，也稱為 taVNS。...
Oct 22 2026
研究前沿｜隨機對照研究證實，經皮耳迷走神經刺激能有效減輕肩關節鏡手術後的反彈性疼痛
簡介 神經阻滯消退時的疼痛 肩關節鏡手術後，疼痛起初可能控制良好，但隨著神經阻滯消退，疼痛可能突然加劇。這種由輕微疼痛轉為劇烈疼痛的過程稱為反彈痛，可能干擾休息與術後恢復。在阻滯作用逐漸減弱時維持穩定鎮痛，仍是圍手術期疼痛管理的重要挑戰。 2026年9月15日，Jun Zhang及其同事在《Regional Anesthesia & Pain Medicine》發表一項隨機、假刺激對照試驗，研究經皮耳部迷走神經刺激（taVNS）是否能降低肩關節鏡手術後反彈痛的發生率。 研究納入120名患者，將taVNS與假刺激，和常規麻醉及鎮痛方案進行比較。手術後24小時內，taVNS組較少出現反彈痛，部分恢復及睡眠指標也有所改善。然而，平均疼痛分數的下降幅度很小，兩組鎮痛藥使用量的差異未達統計學顯著。 背景 反彈痛管理的缺口 單次肌間溝臂叢神經阻滯（ISB）是肩部手術常用的區域鎮痛技術。局部麻醉劑作用於神經周圍，可提供約12至24小時的鎮痛，但藥效消退時，手術部位的疼痛可能迅速出現。因此，評估鎮痛策略時應單獨關注反彈痛：單日平均疼痛分數可能無法充分反映這種急劇而短暫的變化。 連續神經周圍導管及輔助藥物有助於處理這個問題，但也會增加操作、管理或藥物相關負擔。taVNS透過貼於耳部皮膚的電極刺激迷走神經耳支，為研究輔助鎮痛提供另一途徑。其給予方式不同於植入式迷走神經刺激、經皮頸部刺激及針刺式耳部神經調節。 過去研究曾探討耳部神經刺激對術後疼痛的影響，但針對單次ISB後反彈痛的證據仍有限。本試驗事先將反彈痛指定為主要終點，並在既有多模式鎮痛基礎上測試taVNS的附加效果。 方法 隨機比較與刺激方案 這項單中心試驗在中國浙江省德清縣人民醫院進行。在接受篩查的142人中，120名符合條件且安排接受肩關節鏡手術的患者按1:1隨機分組，每組60人。所有患者均完成追蹤，並納入意向治療分析。患者、結果評估者及資料分析人員均保持盲法；負責施加刺激的人員知道分組。 兩組均接受全身麻醉、一次性超聲引導ISB，以及標準化靜脈布洛芬和患者自控舒芬太尼鎮痛。ISB使用15毫升0.5%羅哌卡因。taVNS施加於左側耳甲艇，頻率30 Hz、脈衝寬度250 μs，刺激30秒、休息30秒交替進行。強度逐步提高，直到患者感到明顯麻刺感，再降低至患者確認無感覺的程度。首次治療在術前等候區開始，拔管後轉入麻醉後照護單位前持續進行。術後第1及第2天早上各進行一次2小時治療。假刺激組接受相同的電極放置及感覺閾值測試，但治療期間裝置輸出設定為零。 主要結果是手術後24小時內反彈痛的發生率。研究人員使用0至10分數字評分量表（NRS），將反彈痛定義為阻滯消退後疼痛由≤3升至≥7，且至少上升4分。阻滯消退是根據疼痛變化推定，並未透過連續感覺檢查確認。次要結果包括術後6、12、24及48小時的疼痛與舒芬太尼累積用量、恢復品質、睡眠品質及不良事件。主要結果採用卡方檢驗分析，重複測量的次要結果採用混合效應模型。恢復及睡眠分數的時間點比較進行Bonferroni校正。樣本量按主要終點估算；次要結果分析屬探索性質。 結果 主要終點與效果量...
Oct 13 2026
2026 世界心理健康日：主題與有意義的行動
2026 世界心理健康日為 10 月 10 日星期六。世界衛生組織（WHO）與 World Federation for Mental Health（WFMH）公布的官方主題是「Lived experiences heard: real voices, real change」[1], [2]。今年的倡議重點，是傾聽具有心理健康相關親身經驗的人，並讓他們真正參與影響自身生活的決策、服務與政策。 個人、職場與社區都可以透過實際支持、自願參與的對話、心理健康倡議活動，以及在活動日之後持續進行的行動來參與。真正有意義的參與不需要大型活動，也不一定需要預算。2026 世界心理健康日的核心，是把「提高關注」與「傾聽」轉化為真正的參與及長期支持。 2026 世界心理健康日的主題是什麼？ 2026 世界心理健康日的官方主題是「Lived...
Oct 10 2026
Research Frontiers｜33 萬人睡眠數據顯示：健康睡眠模式與較低失智症風險相關
中年睡眠與大腦健康 中年時期的睡眠習慣，和十多年後的失智症風險有什麼關係？一項超過 33 萬人的研究，同時分析多項睡眠特徵，包括每天的睡眠時間、頻繁失眠與白天嗜睡，評估這些特徵和日後失智症之間的關聯。 這項研究由 Tao Wei、Jie Chang 與同事進行，並於 2025 年 9 月 30 日發表在 Alzheimer's Research & Therapy。研究使用 UK Biobank 資料，參與者在納入研究時年齡為 40 至...
Oct 10 2026
